Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
KEYWORDS: dabigatran, warfarin, people, manufacturer, erg, treatment, daily, committee, twice daily, twice, stroke, inr, compared, years, dabigatran twice

by people with the condition, those who represent them, and clinical specialists. It also took into account the effective use of NHS resources. 4.2 The Committee heard from the clinical specialists and patient experts that the current standard treatment for the prevention of stroke and systemic embolism in people with atrial fibrillation is warfarin, and that because of its lower efficacy, aspirin is used only in people for whom warfarin is unsuitable. The Committee also heard that warfarin, although an effective treatment, is associated with a number of problems. The main concerns for people with atrial fibrillation were fear of having a stroke and anxiety about the difficulty of keeping the INR within the satisfactory therapeutic range. The Committee heard from the patient experts that stroke is a major concern for people with atrial fibrillation and that stroke severity is usually greater in this group than in people who have strokes from other causes. The patient experts also highlighted that many people taking warfarin are outside their target therapeutic INR range at any 1 time and that warfarin, unlike dabigatran, is associated with a number of inconveniences that make adherence difficult. These include numerous food and drug interactions that can
